Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication
17/03/2026 12:29
March 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: RECEIVES PERMISSION TO IMPORT DURVALUMAB (IMFINZI) FOR ADDITIONAL INDICATION Source text: ID:nBSE4YQpNZ Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan